Celcuity to Participate in Cowen’s 44th Annual Health Care Conference

Rhea-AI Summary

Celcuity Inc. (CELC) to participate in Cowen’s 44th Annual Health Care Conference with CEO Brian Sullivan scheduled for a fireside chat. Live webcast details provided.

MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in Cowen’s 44^th Annual Health Care Conference to be held in Boston on March 4-6, 2024.

Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a fireside chat at 2:10 p.m. ET on Wednesday, March 6, 2024. A live webcast of the event will be available using this weblink https://wsw.com/webcast/cowen154/celc/1980218. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after.

About Celcuity

Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is currently enrolling patients. The company's CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Further information about Celcuity can be found at Celcuity.com. Follow us on LinkedIn and Twitter.

Contacts:

Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123

ICR Westwicke
Maria Yonkoski, maria.yonkoski@westwicke.com
(203) 682-7167

FAQ

When is Celcuity Inc. participating in Cowen’s 44th Annual Health Care Conference?

Celcuity Inc. (CELC) is participating in Cowen’s 44th Annual Health Care Conference on March 4-6, 2024.

Who is scheduled for a fireside chat at the conference?

Brian Sullivan, the Chief Executive Officer, and Co-founder of Celcuity Inc., is scheduled for a fireside chat at 2:10 p.m. ET on Wednesday, March 6, 2024.

Where can the live webcast of the event be accessed?

The live webcast of the event can be accessed using the weblink https://wsw.com/webcast/cowen154/celc/1980218 or from the Investors section of Celcuity Inc.'s website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after.